MX2023011619A - Nuevos anticuerpos anti-sema3a y usos de los mismos. - Google Patents

Nuevos anticuerpos anti-sema3a y usos de los mismos.

Info

Publication number
MX2023011619A
MX2023011619A MX2023011619A MX2023011619A MX2023011619A MX 2023011619 A MX2023011619 A MX 2023011619A MX 2023011619 A MX2023011619 A MX 2023011619A MX 2023011619 A MX2023011619 A MX 2023011619A MX 2023011619 A MX2023011619 A MX 2023011619A
Authority
MX
Mexico
Prior art keywords
sema3a
seq
sequence
binds
activity
Prior art date
Application number
MX2023011619A
Other languages
English (en)
Inventor
Ingo Flamme
Dorian Schönfeld
Ernst Weber
Philipp Ellinger
Karoline DRÖBNER
Katharina Filarsky
Eser Fionnuala Mary Mcaleese
Winfried Wunderlich
Antje Schmidt
Yalda Sedaghat
Kenneth Young
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2023011619A publication Critical patent/MX2023011619A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un anticuerpo aislado o su fragmento de unión a antígeno que se une con Sema3A humana. El anticuerpo aislado o fragmento de unión a antígeno de acuerdo con la presente invención i) se une con Sema3A humana de la secuencia de SEQ ID NO: 600 con una constante de disociación (KD) = 50 nM, = 20 nM, = 10 nM, = 1 nM o = 0,1 nM; ii) reacciona en forma cruzada con Sema3A de ratón, cinomolgus, rata, cerdo y/o perro, en particular en donde dicho anticuerpo aislado o su fragmento de unión a antígeno se une con Sema3A de ratón, cinomolgus, rata, cerdo y/o perro con una constante de disociación (KD) = 50 nM, = 20 nM, = 10 nM, = 1 nM o = 0,1 nM; iii) se une con Sema3A humana de la secuencia de SEQ ID NO: 600 con una actividad de unión medida por resonancia de plasmón superficial (SPR) de = 60%, = 70%, = 80% o = 90%; iv) inhibe la actividad de Sema3A humana de la secuencia de SEQ ID NO: 600 en un ensayo de migración de células mesangiales in vitro con una EC50 de = 10 nM, = 5 nM, = 2,5 nM o = 1 nM; v) inhibe la actividad de Sema3A humana de la secuencia de SEQ ID NO: 600 en un ensayo de colapso de cono de crecimiento in vitro con una EC50 de = 50 nM, = 25 nM, = 10 nM o = 5 nM; vi) inhibe la actividad de Sema3A humana de la secuencia de SEQ ID NO: 600 en un ensayo de repulsión HUVEC in vitro con una EC50 de = 1 nM o = 0,3 nM, = 0,1 nM, = 0,07 nM, = 0,06 nM y/o vii) exhibe una mayor potencia contra Sema3A celular, de la secuencia de SEQ ID NO: 600, repulsión inducida por HUVEC.
MX2023011619A 2021-03-30 2022-03-28 Nuevos anticuerpos anti-sema3a y usos de los mismos. MX2023011619A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21165960 2021-03-30
PCT/EP2022/058123 WO2022207554A1 (en) 2021-03-30 2022-03-28 Anti-sema3a antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023011619A true MX2023011619A (es) 2023-10-11

Family

ID=75302351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011619A MX2023011619A (es) 2021-03-30 2022-03-28 Nuevos anticuerpos anti-sema3a y usos de los mismos.

Country Status (14)

Country Link
US (1) US20220389096A1 (es)
EP (1) EP4314047A1 (es)
JP (1) JP2024512633A (es)
KR (1) KR20230162800A (es)
CN (1) CN117396504A (es)
AR (1) AR125240A1 (es)
AU (1) AU2022251786A1 (es)
BR (1) BR112023018061A2 (es)
CA (1) CA3215274A1 (es)
IL (1) IL307233A (es)
MX (1) MX2023011619A (es)
PE (1) PE20240357A1 (es)
TW (1) TW202304975A (es)
WO (1) WO2022207554A1 (es)

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DE69830315T2 (de) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008112640A2 (en) 2007-03-09 2008-09-18 Sinomab Bioscience Limited Construction and use of a functionally human antibody library with maximized repertoire diversity
DK2955195T3 (da) * 2013-02-06 2019-05-06 Univ Yokohama City Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme
WO2017074013A1 (ko) 2015-10-27 2017-05-04 사회복지법인 삼성생명공익재단 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도
CR20210559A (es) * 2019-05-09 2021-12-23 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
WO2020261281A1 (en) * 2019-06-27 2020-12-30 Ramot At Tel-Aviv University Ltd. Semaphorin 3a antibodies and uses thereof

Also Published As

Publication number Publication date
BR112023018061A2 (pt) 2023-10-03
EP4314047A1 (en) 2024-02-07
TW202304975A (zh) 2023-02-01
US20220389096A1 (en) 2022-12-08
IL307233A (en) 2023-11-01
CA3215274A1 (en) 2022-10-06
PE20240357A1 (es) 2024-02-27
AR125240A1 (es) 2023-06-28
JP2024512633A (ja) 2024-03-19
AU2022251786A1 (en) 2023-10-05
WO2022207554A1 (en) 2022-10-06
KR20230162800A (ko) 2023-11-28
CN117396504A (zh) 2024-01-12

Similar Documents

Publication Publication Date Title
RU2009111884A (ru) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
CN111108119B (zh) 新型抗CD3ε抗体
RU2005132389A (ru) Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами
RS52592B (en) ANTI-HEPCIDINE ANTIBODIES AND THEIR USE
HRP20150162T1 (hr) Antikin antitijela koja se vežu na višestruke cc kemokine
JP2016135783A5 (es)
RS52804B (en) HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND THEIR USE
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
AU2013310924B2 (en) Method for producing antibody molecules having inter-species, intra-target cross-reactivity
RS53595B1 (en) ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE
RU2013138469A (ru) АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ
WO2007111714B1 (en) Il-21 antagonists
CN1997893A (zh) 抗体测定法
CO6231000A2 (es) Anticuerpos contra de erbb3 y usos de los mismos
JP2021501744A5 (es)
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
RS54066B1 (en) COMPLETELY HUMAN ANTI-VAP-1 MONOCLONAL ANTIBODIES
RU2011149334A (ru) Анти-il-17f антитела и способы их применения
AU6943800A (en) Antibodies specific for fullerenes
CN112111011B (zh) 一种特异性抗噻虫嗪抗体的可变区序列及其重组全长抗体
MX2023011619A (es) Nuevos anticuerpos anti-sema3a y usos de los mismos.
DE69937369D1 (de) CCR5 Antikörper PA14
RU2010152690A (ru) Белки, связывающие рецептор интерлейкина-21
US11884743B2 (en) Preparation and application of an intact recombinant antibody specific to clothianidin based on the identified variable region sequence
CN108456252B (zh) 高特异性的抗兔IgG天然构象单克隆抗体